Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The FDA has issued draft guidance on key information and informed consent, as well as published a white paper on artificial intelligence and medical products. Additionally, the FDA released draft guidance on new dietary ingredient notification procedures and timelines. The agency also finalized a guidance on medical device cybersecurity in late 2023 and recently published select updates. Furthermore, the FDA detailed actions it intends to take regarding the uses of AI across the medical product life cycle.
Out in the Open: HHS’s New AI Transparency Rule https://t.co/oeHUEcYSVm #artificialintelligence #health #AIlaw @SheppardMullin https://t.co/Izyy0LUswt
FDA Publishes Paper Detailing Actions It Intends to Take Regarding the Uses of AI Across the Medical Product Life Cycle https://t.co/Ul9bzEYvYl #artificialintelligence #medicalproducts #FDA @NelsonMullins https://t.co/WwVGHvL2dO
FDA Publishes Paper Detailing Actions It Intends to Take Regarding the Uses of AI Across the Medical Product Life Cycle https://t.co/NiwWX7klYh | by @NelsonMullins
